Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck.

Trial Profile

Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2011

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Head and neck cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 17 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top